28664-62-2

Usage

Uses

Used in Pharmaceutical Industry:
2-phenoxypyridin-3-amine is used as a building block for the synthesis of biologically active molecules, leveraging its unique chemical structure to contribute to the development of new drugs. Its potential role in medicinal chemistry is attributed to its ability to form part of complex molecular frameworks that can interact with biological targets, thus offering therapeutic benefits.
Used in Agrochemical Industry:
In the agrochemical sector, 2-phenoxypyridin-3-amine is utilized as a precursor in the production of pesticides and herbicides. Its chemical properties allow it to be incorporated into compounds that can effectively control, repel, or kill unwanted organisms in agricultural settings, thereby enhancing crop protection and yield.
The versatility of 2-phenoxypyridin-3-amine across different industries underscores its importance as a chemical intermediate, with applications ranging from healthcare to agriculture, reflecting its broad utility in creating products that address various needs.

Upstream product

• 76893-44-2 3-nitropyridine-2-phenyl ether 
• 1480-87-1 2-fluoro-3-nitropyridine 
• 108-95-2 phenol 
• 5470-18-8 2-Chloro-3-nitropyridine 

Downstream Products

• 476453-77-7 N-(2-phenoxy-3-pyridinyl)methanesulfonimide 
• 1400637-82-2 C₂₁H₁₉BrN₂O₃ 
• 1400637-67-3 C₂₁H₁₉⁽¹⁸⁾FN₂O₃ 
• 1245623-84-0 N-[2-(2-fluoroethoxy)benzyl]-N-(2-phenoxy pyridin-3-yl)acetamide 
• 1207345-63-8 N-[2-(2-fluoroethoxy)-5-methoxybenzyl]-N-(2-phenoxypyridin-3-yl)acetamide 
• 1400637-54-8 C₂₁H₁₉FN₂O₃ 
• 1423008-63-2 C₁₈H₁₃F₂N₃O₂ 

Relevant academic research and scientific papers

Chemical validation of a druggable site on Hsp27/HSPB1 using in silico solvent mapping and biophysical methods

Destabilizing mutations in small heat shock proteins (sHsps) are linked to multiple diseases; however, sHsps are conformationally dynamic, lack enzymatic function and have no endogenous chemical ligands. These factors render sHsps as classically “undruggable” targets and make it particularly challenging to identify molecules that might bind and stabilize them. To explore potential solutions, we designed a multi-pronged screening workflow involving a combination of computational and biophysical ligand-discovery platforms. Using the core domain of the sHsp family member Hsp27/HSPB1 (Hsp27c) as a target, we applied mixed solvent molecular dynamics (MixMD) to predict three possible binding sites, which we confirmed using NMR-based solvent mapping. Using this knowledge, we then used NMR spectroscopy to carry out a fragment-based drug discovery (FBDD) screen, ultimately identifying two fragments that bind to one of these sites. A medicinal chemistry effort improved the affinity of one fragment by ~50-fold (16 μM), while maintaining good ligand efficiency (~0.32 kcal/mol/non-hydrogen atom). Finally, we found that binding to this site partially restored the stability of disease-associated Hsp27 variants, in a redox-dependent manner. Together, these experiments suggest a new and unexpected binding site on Hsp27, which might be exploited to build chemical probes.

Discovery of dually acting small-molecule inhibitors of cancer-resistance relevant receptor tyrosine kinases EGFR and IGF-1R

Novel benzo-anellated furo- and pyrrolo[2,3-b]pyridines with a 4-benzylamine substitution have been evaluated as inhibitors of the epidermal growth factor receptor (EGFR). Substituent effects on the determined protein kinase affinity have been discussed based on varied benzylamine residues at the differently substituted molecular scaffolds. Docking studies were carried out in order to explore the potential binding modes of the novel inhibitors. The observed activity data encouraged the measurement of the inhibition of the insulin-like growth factor receptor (IGF-1R), which is known to play an important role in the cancer-resistance development against EGFR inhibitors via receptor heterodimerizations with IGF-1R. We identified novel dual inhibitors of both kinases and report their first cancer cell growth inhibition data.

Synthesis of pyrido[2,3-b][1,4]benzoxazepines via a Friedel-Crafts cyclization

(Formula Presented.) An efficient and practical method has been developed for the synthesis of 6-aryl-substituted pyrido[2,3-b][1,4]benzoxazepines via a Friedel-Crafts reaction of readily accessible 2-phenoxypyridin-3-amines and aromatic acids.

For radioactive-derwed Pyridinil deriv. in vivo imaging

The present invention provides a novel radiolabeled aryloxyalinine derivative suitable for in vivo imaging. In comparison to known aryloxyalinine derivative in vivo imaging agents, the in vivo imaging agent of the present invention has better properties for in vivo imaging. The in vivo imaging agent of the present invention demonstrates good selective binding to the peripheral benzodiazepine receptor (PBR), in combination with good brain uptake and in vivo kinetics following administration to a subject.

Discovery of 2-(phenoxypyridine)-3-phenylureas as small molecule P2Y 1 antagonists

Two distinct G protein-coupled purinergic receptors, P2Y1 and P2Y12, mediate ADP-driven platelet activation. The clinical effectiveness of P2Y12 blockade is well established. Recent preclinical data suggest that P2Y1

Exploration of the structure-activity relationship of the diaryl anilide class of ligands for translocator protein - Potential novel positron emitting tomography imaging agents

A series of novel ligands based on the diaryl anilide (DAA) class of translocator protein (TSPO) ligands was synthesised and evaluated as potential positron emitting tomography (PET) ligands for imaging TPSO in vivo. Fluorine-18 labelling of the molecules was achieved using direct radiolabelling or synthon based labelling approaches. Several of the ligands prepared have promising profiles as potential TSPO PET imaging ligands and will be evaluated further as potential clinical imaging agents.

Discovery and selectivity-profiling of 4-benzylamino 1-aza-9-oxafluorene derivatives as lead structures for IGF-1R inhibitors

Recently the insuline-like growth factor receptor (IGF-1R) emerged as a promising target structure for the development of novel anti-cancer agents. IGF-1R plays a central role in both tumour progression and resistance development against anti-cancer drugs. We discovered 1-aza-9-oxafluorene derivatives as novel lead structures with submicromolar activities against IGF-1R. Structure-activity relationships (SARs) on a series of related receptor tyrosine kinases (RTKs) are discussed in the context of available crystal structures. A preliminary selectivity-profiling is demonstrated for the first compound series. Antiproliferative tumour cell line screening studies yielded one candidate as a promising cytostatic agent without significant toxic effects.

Spectral and crystallographic study of pyridinic analogues of nimesulide: Determination of the active form of methanesulfonamides as COX-2 selective inhibitors

Compound 7, N-(3-phenoxy-4-pyridinyl)trifluoromethanesulfonamide, showed in vitro (whole blood assay) a strong inhibitory activity on the two cyclooxygenase (COX) enzymes (IC50(COX1) = 2.2 μM and IC50(COX-2) = 0.4 μM), being more act